# **Special Issue**

# Molecular Imaging in Oncology: Radiopharmaceuticals for PET and SPECT 2022

## Message from the Guest Editor

Molecular imaging can partly be defined as in vivo imaging of biological or biochemical processes using various markers. Nuclear medicine employs such molecular imaging technologies as SPECT and PET that require radiolabeled tracers (radiopharmaceuticals) as markers. The use of radiopharmaceuticals for the imaging of the biochemical changes that come with any disease provides functional imaging.

Radiopharmaceuticals can be specific to certain biological targets characteristic to a disease. Novel clinical applications of radiopharmaceuticals promote great developments in nuclear medicine. This Special Issue entitled "Molecular Imaging in Oncology: Radiopharmaceuticals for PET and SPECT 2022" aims to focus on the state of the art in this field. You are cordially invited to contribute to this Special Issue with original articles as well as reviews.

## **Guest Editor**

Prof. Dr. Junbo Zhang

Key Laboratory of Radiopharmaceuticals of Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, China

## Deadline for manuscript submissions

closed (30 March 2023)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



## mdpi.com/si/112088

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Editor-in-Chief

## Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

